EICHORCondition: Solid Tumors · Advanced Solid Tumors · Metastatic Solid Tumors · Sponsor: Incyte Corporation
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| The Angeles Clinic and Research Institute | Los Angeles, California, United States | — |
| Valkyrie Clinical Trials | Panorama City, California, United States | — |
| University of Florida Health Shands Hospital | Gainesville, Florida, United States | — |
| Cancer and Hematology Centers of Western Michigan-Start Midwest | Grand Rapids, Michigan, United States | — |
| Hackensack University Medical Center | Hackensack, New Jersey, United States | — |
| Carolina Bio Oncology | Huntersville, North Carolina, United States | — |
| Providence Cancer Institute Franz Clinic | Portland, Oregon, United States | — |
| Upmc Cancercenter | Pittsburgh, Pennsylvania, United States | — |
| South Texas Accelerated Research Therapeutics | San Antonio, Texas, United States | — |
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06873789